JP2005530484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530484A5 JP2005530484A5 JP2003565508A JP2003565508A JP2005530484A5 JP 2005530484 A5 JP2005530484 A5 JP 2005530484A5 JP 2003565508 A JP2003565508 A JP 2003565508A JP 2003565508 A JP2003565508 A JP 2003565508A JP 2005530484 A5 JP2005530484 A5 JP 2005530484A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- angiogenesis
- albumin fusion
- albumin
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000009027 Albumins Human genes 0.000 claims 75
- 108010088751 Albumins Proteins 0.000 claims 75
- 108020001507 fusion proteins Proteins 0.000 claims 57
- 102000037865 fusion proteins Human genes 0.000 claims 57
- 230000033115 angiogenesis Effects 0.000 claims 45
- 239000012634 fragment Substances 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 230000002401 inhibitory effect Effects 0.000 claims 28
- 238000000034 method Methods 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 241000124008 Mammalia Species 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 230000001419 dependent effect Effects 0.000 claims 11
- 238000001727 in vivo Methods 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 230000004927 fusion Effects 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 4
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 230000001772 anti-angiogenic effect Effects 0.000 claims 4
- 230000004071 biological effect Effects 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010000050 Abdominal adhesions Diseases 0.000 claims 1
- 102400000068 Angiostatin Human genes 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000003732 Cat-scratch disease Diseases 0.000 claims 1
- 102400001047 Endostatin Human genes 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000003527 anti-angiogenesis Effects 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- 230000002380 cytological effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010016629 fibroma Diseases 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000002390 hyperplastic effect Effects 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35554702P | 2002-02-07 | 2002-02-07 | |
| PCT/IB2003/000433 WO2003066085A1 (en) | 2002-02-07 | 2003-02-07 | Albumin-fused anti-angiogenesis peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530484A JP2005530484A (ja) | 2005-10-13 |
| JP2005530484A5 true JP2005530484A5 (OSRAM) | 2005-12-22 |
Family
ID=27734531
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565508A Pending JP2005530484A (ja) | 2002-02-07 | 2003-02-07 | アルブミン融合抗血管形成ペプチド |
| JP2003565501A Pending JP2005516607A (ja) | 2002-02-07 | 2003-02-07 | Ｈｉｖ阻害タンパク質 |
| JP2003566175A Pending JP2005538932A (ja) | 2002-02-07 | 2003-02-07 | アルブミン融合クニッツドメインペプチド |
| JP2009239593A Pending JP2010046076A (ja) | 2002-02-07 | 2009-10-16 | アルブミン融合クニッツドメインペプチド |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565501A Pending JP2005516607A (ja) | 2002-02-07 | 2003-02-07 | Ｈｉｖ阻害タンパク質 |
| JP2003566175A Pending JP2005538932A (ja) | 2002-02-07 | 2003-02-07 | アルブミン融合クニッツドメインペプチド |
| JP2009239593A Pending JP2010046076A (ja) | 2002-02-07 | 2009-10-16 | アルブミン融合クニッツドメインペプチド |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20060122374A1 (OSRAM) |
| EP (4) | EP1572930A4 (OSRAM) |
| JP (4) | JP2005530484A (OSRAM) |
| KR (4) | KR20050002823A (OSRAM) |
| CN (3) | CN1646154B (OSRAM) |
| AU (5) | AU2003210885B2 (OSRAM) |
| CA (3) | CA2475382A1 (OSRAM) |
| NZ (3) | NZ534310A (OSRAM) |
| WO (3) | WO2003066078A1 (OSRAM) |
| ZA (3) | ZA200406124B (OSRAM) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| ATE529444T1 (de) | 1994-01-11 | 2011-11-15 | Dyax Corp | Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| DK2311432T3 (en) * | 2002-06-07 | 2015-02-02 | Dyax Corp | Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure |
| GB0217033D0 (en) * | 2002-07-23 | 2002-08-28 | Delta Biotechnology Ltd | Gene and polypeptide sequences |
| TR201900937T4 (tr) * | 2002-08-28 | 2019-02-21 | Dyax Corp | Organların ve dokuların muhafaza edilmesine yönelik yöntem. |
| MXPA05006688A (es) | 2002-12-19 | 2006-02-22 | Nektar Therapeutics Al Corp | Conjugados de polimero con una variante de cianovirina. |
| CA2513213C (en) * | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6989369B2 (en) | 2003-02-07 | 2006-01-24 | Dyax Corp. | Kunitz domain peptides |
| US7524811B2 (en) * | 2003-08-29 | 2009-04-28 | Children's Medical Center Corporation | Anti-angiogenic peptides from the N-terminus of endostatin |
| EP1687426B1 (en) * | 2003-08-29 | 2008-07-16 | Children's Medical Center Corporation | Antiangiogenicpeptides for treating or preventing endometriosis |
| US9057061B2 (en) | 2003-12-23 | 2015-06-16 | Novozymes Biopharma Dk A/S | Gene expression technique |
| WO2006067511A1 (en) | 2004-12-23 | 2006-06-29 | Novozymes Delta Limited | Gene expression technique |
| GB0329722D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Modified plasmid and use thereof |
| WO2005063282A1 (en) * | 2003-12-23 | 2005-07-14 | Centocor, Inc. | Anti-retroviral agents, compositions, methods and uses |
| GB0329681D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
| US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| AU2011218732B2 (en) * | 2004-09-27 | 2013-07-04 | Takeda Pharmaceutical Company Limited | Kallikrein Inhibitors and Uses Thereof |
| ES2325344B1 (es) * | 2004-11-02 | 2010-06-09 | Univ Madrid Autonoma | Inhibidores de angiogenesis multifuncionales y multivalentes. |
| CA2587775A1 (en) * | 2004-11-22 | 2006-06-01 | Dyax Corp. | Plasmin-inhibitory therapies |
| US8828703B2 (en) * | 2005-12-29 | 2014-09-09 | Dyax Corp. | Protease inhibition |
| CN100475270C (zh) * | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| ES2601554T3 (es) | 2006-03-16 | 2017-02-15 | Dyax Corp. | Péptidos inhibidores de calicreína plasmática para uso en el tratamiento de trastornos oftálmicos |
| EP2423219B1 (en) | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
| US20090022720A1 (en) * | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
| CA2695830A1 (en) | 2007-08-08 | 2009-02-12 | Novozymes Biopharma Dk A/S | Transferrin variants and conjugates |
| CA2695012A1 (en) * | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| US9025330B2 (en) | 2007-09-30 | 2015-05-05 | Alcatel Lucent | Recirculating gas rack cooling architecture |
| US8632986B2 (en) | 2008-10-28 | 2014-01-21 | Uladzimir A. Murauski | Methods and kits for detection of toxemia |
| US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| WO2010092135A2 (en) | 2009-02-11 | 2010-08-19 | Novozymes Biopharma Uk Ltd. | Albumin variants and conjugates |
| EP2427486B1 (en) | 2009-05-07 | 2015-02-25 | Novozymes Biopharma DK A/S | Method for purifying albumin |
| CN102741280B (zh) | 2009-10-30 | 2015-12-02 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
| ES2688093T3 (es) | 2010-01-06 | 2018-10-30 | Dyax Corp. | Proteínas de unión a calicreína plasmática |
| CN101875693B (zh) * | 2010-01-22 | 2012-07-18 | 成都正能生物技术有限责任公司 | 具备抗血管生成活性的白蛋白变异体及其制备方法 |
| CN106977608A (zh) * | 2010-04-09 | 2017-07-25 | 阿尔布麦狄克斯公司 | 白蛋白衍生物和变体 |
| JP5757639B2 (ja) * | 2010-09-14 | 2015-07-29 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | セルピンフィンガー融合ポリペプチド |
| CN102453097A (zh) * | 2010-10-27 | 2012-05-16 | 上海科新生物技术股份有限公司 | 抑制血管新生的融合蛋白vf及药物组合物和应用 |
| US20130225496A1 (en) | 2010-11-01 | 2013-08-29 | Novozymes Biopharma Dk A/S | Albumin Variants |
| IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| MX353816B (es) | 2011-05-05 | 2018-01-30 | Albumedix As | Variantes de albumina. |
| JP6073888B2 (ja) * | 2011-08-17 | 2017-02-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレート | トランスフェリン−タムスタチン融合タンパク質並びにそれを作製する方法及びそれを使用する方法 |
| CN102532326B (zh) * | 2011-11-18 | 2017-06-09 | 南京大学 | 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用 |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| US9528992B2 (en) | 2012-02-20 | 2016-12-27 | Uladzimir A. Murauski | Methods and kits for detection of active malignancy |
| MX2014010278A (es) | 2012-03-16 | 2015-03-05 | Novozymes Biopharma Dk As | Variantes de albumina. |
| EP2890389A1 (en) * | 2012-08-28 | 2015-07-08 | Novartis AG | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| WO2014072481A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
| HUE044285T2 (hu) | 2013-01-20 | 2019-10-28 | Dyax Corp | PKal-mediálta rendellenességek értékelése, vizsgálata és kezelése |
| WO2014125082A1 (en) | 2013-02-16 | 2014-08-21 | Novozymes Biopharma Dk A/S | Pharmacokinetic animal model |
| EP2994483A4 (en) * | 2013-05-06 | 2017-02-08 | Cell Machines, Inc. | Methods and compositions related to large scale production of proteins |
| CN103333255A (zh) * | 2013-06-28 | 2013-10-02 | 复旦大学 | 一种长效hiv‐1膜融合抑制剂 |
| EP3122782A4 (en) | 2014-03-27 | 2017-09-13 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| DE102014112212A1 (de) | 2014-08-26 | 2016-03-03 | Akesion Gmbh | Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen |
| CN105440138A (zh) * | 2014-09-30 | 2016-03-30 | 复旦大学 | 一种长效内皮抑素融合蛋白的制备方法和用途 |
| BR112017025554B1 (pt) | 2015-05-30 | 2024-03-12 | Genomatica, Inc. | Composição, e, método para produzir um polímero, resina ou artigo de fabricação |
| CN104926946B (zh) * | 2015-07-13 | 2021-09-17 | 中国科学院广州生物医药与健康研究院 | 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用 |
| WO2017029407A1 (en) | 2015-08-20 | 2017-02-23 | Albumedix A/S | Albumin variants and conjugates |
| PT3348635T (pt) * | 2015-09-08 | 2021-03-15 | Japan Chem Res | Novo mutante de albumina do soro humano |
| CN110498851B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 一种抗肿瘤蛋白内皮抑素的衍生物及应用 |
| BR112018011622A2 (pt) | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
| JP7146637B2 (ja) | 2015-12-22 | 2022-10-04 | アルブミディクス リミティド | 改善されたタンパク質発現株 |
| WO2017112847A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix A/S | Improved protein expression strains |
| CN105646717B (zh) * | 2016-01-26 | 2020-06-09 | 复旦大学 | 一种长效hiv融合抑制剂及其应用 |
| DK3642343T3 (en) | 2017-06-20 | 2022-03-14 | Albumedix Ltd | Improved protein expression strains |
| WO2019032472A1 (en) * | 2017-08-08 | 2019-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | HIGH AFFINITY MODIFIED MATRIX INHIBITOR |
| WO2019043649A2 (en) * | 2017-08-31 | 2019-03-07 | Singapore Health Services Pte Ltd | ANGIO -3 FOR THE TREATMENT OF RETINAL ANGIOGENIC DISEASES |
| SI3684786T1 (sl) | 2017-09-22 | 2025-03-31 | Centre National De La Recherche Scientifique (Cnrs) | Mutirani glikoprotein virusa vezikularnega stomatitisa |
| ES2980055T3 (es) * | 2017-09-22 | 2024-09-27 | Kite Pharma Inc | Polipéptidos quiméricos y usos de los mismos |
| CN109879969B (zh) * | 2017-12-06 | 2024-04-09 | 天士力生物医药股份有限公司 | 一种hm-3融合蛋白及其应用 |
| CA3117961A1 (en) | 2018-10-29 | 2020-05-07 | Spin Therapeutics, Llc | Compositions and methods for alpha-1-antitrypsin disorders |
| DE102019000490A1 (de) * | 2019-01-23 | 2020-07-23 | HAEMES Verwaltungsgesellschaft mbH | Verwendung von Oligonukleotiden für die Behandlung von Tumoren |
| TWI881973B (zh) | 2019-04-16 | 2025-05-01 | 日商武田藥品工業股份有限公司 | 定量功能性c1酯酶抑制子（fc1-inh）之方法 |
| CN111995686B (zh) * | 2019-05-27 | 2022-06-14 | 兰州大学 | 一种具有抗血管生成活性的药物及其制备方法 |
| CA3167336A1 (en) | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| CN111494604B (zh) * | 2020-05-11 | 2022-05-06 | 中国药科大学 | 蓝藻抗病毒蛋白n在制备抗炎药物中的应用 |
| CN111560049B (zh) * | 2020-05-17 | 2022-05-17 | 浙江大学 | 两性离子多肽及其衍生物以及以其为基础的纳米药物 |
| US20230322882A1 (en) * | 2020-07-08 | 2023-10-12 | Nanjing Normal University | Fusion Polypeptide and Polypeptide Dimer, and Use Thereof |
| CA3255646A1 (en) * | 2022-03-09 | 2023-09-14 | Immunofyx | N-TERMINAL FC CONJUGATED CANCER IMMUNOTHERAPY AGENTS |
| JP7747395B2 (ja) * | 2023-03-28 | 2025-10-01 | 株式会社エヌビィー健康研究所 | 抗体、核酸、細胞、及び医薬 |
| EP4442251A1 (en) | 2023-04-05 | 2024-10-09 | Albumedix Ltd | Formulations and uses thereof |
| AU2024353718A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| CN117924430B (zh) * | 2024-03-22 | 2024-06-28 | 中国人民解放军军事科学院军事医学研究院 | 促进血小板生成的tpor结合肽 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US355547A (en) | 1887-01-04 | mebcee | ||
| CA91311A (en) | 1904-11-15 | 1905-01-31 | The Canadian Westinghouse Company, Limited | Single phase alternating current motors |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8510219D0 (en) | 1985-04-22 | 1985-05-30 | Bass Plc | Isolation of fermentation products |
| JPS6296086A (ja) | 1985-10-21 | 1987-05-02 | Agency Of Ind Science & Technol | 複合プラスミド |
| US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8615701D0 (en) | 1986-06-27 | 1986-08-06 | Delta Biotechnology Ltd | Stable gene integration vector |
| US4857467A (en) | 1986-07-23 | 1989-08-15 | Phillips Petroleum Company | Carbon and energy source markers for transformation of strains of the genes Pichia |
| GB8620926D0 (en) | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
| EP0286424B1 (en) | 1987-04-09 | 1994-03-16 | Delta Biotechnology Limited | Yeast vector |
| ATE105767T1 (de) | 1987-07-08 | 1994-06-15 | Primtec | Nachdrucksteuerung und schliessen gestapelter formen eines mehrteiligen systems mit zeitlich auseinanderliegenden einspritzperioden. |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| AU633020B2 (en) | 1988-07-23 | 1993-01-21 | Novozymes Delta Limited | New secretory leader sequences |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5766883A (en) * | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| GB8924021D0 (en) | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5602307A (en) | 1992-08-12 | 1997-02-11 | Baylor College Of Medicine | Non-human animal having predefined allele of a cellular adhesion gene |
| DE4244915C2 (de) | 1992-08-14 | 1998-12-03 | Widmar Prof Dr Tanner | DNA-Moleküle codierend Proteine, die an der O-Glykosylierung von Proteinen beteiligt sind |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5489743A (en) | 1993-01-19 | 1996-02-06 | Amgen Inc. | Transgenic animal models for thrombocytopenia |
| US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| DE69533472T2 (de) | 1994-01-11 | 2006-01-12 | Dyax Corp., Cambridge | Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon |
| ATE529444T1 (de) * | 1994-01-11 | 2011-11-15 | Dyax Corp | Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| ATE355379T1 (de) * | 1994-04-26 | 2006-03-15 | Childrens Medical Center | Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese |
| GB9411356D0 (en) | 1994-06-07 | 1994-07-27 | Delta Biotechnology Ltd | Yeast strains |
| US5854205A (en) * | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
| US5854221A (en) * | 1996-12-12 | 1998-12-29 | The Children's Medical Center Corporation | Endothelial cell proliferation inhibitor and method of use |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| US6797488B1 (en) * | 1997-12-08 | 2004-09-28 | Beth Israel Deaconess Medical Center | Methods of producing anti-angiogenic proteins |
| US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| US20030012792A1 (en) * | 1998-05-22 | 2003-01-16 | Holaday John W. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| US6087473A (en) | 1999-05-26 | 2000-07-11 | Zymogenetics, Inc. | Kunitz domain polypeptide and materials and methods for making it |
| GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| US20020048571A1 (en) * | 1999-07-19 | 2002-04-25 | Jeno Gyuris | Chimeric polypeptides of serum albumin and uses related thereto |
| US20010056075A1 (en) * | 1999-07-19 | 2001-12-27 | Jeno Gyuris | Chimeric polypeptides of serum albumin and uses related thereto |
| AU2296301A (en) * | 1999-12-29 | 2001-07-09 | Zymogenetics Inc. | Kunitz domain polypeptide zkun10 |
| AU2001244093A1 (en) | 2000-04-03 | 2001-10-15 | Novozymes A/S | Enzyme tablets for cleaning improvement |
| EP1274720A4 (en) * | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| US6946134B1 (en) * | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1197550A3 (en) * | 2000-08-25 | 2002-11-20 | Pfizer Products Inc. | Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| US20020159992A1 (en) * | 2000-09-29 | 2002-10-31 | Jack Henkin | Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| PT1463751E (pt) * | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
| US6989369B2 (en) * | 2003-02-07 | 2006-01-24 | Dyax Corp. | Kunitz domain peptides |
| US9057061B2 (en) * | 2003-12-23 | 2015-06-16 | Novozymes Biopharma Dk A/S | Gene expression technique |
| GB0329722D0 (en) * | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Modified plasmid and use thereof |
| GB0329681D0 (en) * | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
| CN106977608A (zh) * | 2010-04-09 | 2017-07-25 | 阿尔布麦狄克斯公司 | 白蛋白衍生物和变体 |
-
2003
- 2003-02-07 CA CA002475382A patent/CA2475382A1/en not_active Abandoned
- 2003-02-07 JP JP2003565508A patent/JP2005530484A/ja active Pending
- 2003-02-07 KR KR10-2004-7012256A patent/KR20050002823A/ko not_active Ceased
- 2003-02-07 CA CA002485064A patent/CA2485064A1/en not_active Abandoned
- 2003-02-07 AU AU2003210885A patent/AU2003210885B2/en not_active Ceased
- 2003-02-07 JP JP2003565501A patent/JP2005516607A/ja active Pending
- 2003-02-07 NZ NZ534310A patent/NZ534310A/en not_active IP Right Cessation
- 2003-02-07 KR KR10-2004-7012255A patent/KR20040095217A/ko not_active Ceased
- 2003-02-07 CN CN038076411A patent/CN1646154B/zh not_active Expired - Fee Related
- 2003-02-07 AU AU2003244516A patent/AU2003244516A1/en not_active Abandoned
- 2003-02-07 JP JP2003566175A patent/JP2005538932A/ja active Pending
- 2003-02-07 KR KR10-2004-7012254A patent/KR20040089608A/ko not_active Ceased
- 2003-02-07 WO PCT/IB2003/000434 patent/WO2003066078A1/en not_active Ceased
- 2003-02-07 EP EP03737682A patent/EP1572930A4/en not_active Withdrawn
- 2003-02-07 ZA ZA200406124A patent/ZA200406124B/xx unknown
- 2003-02-07 CN CNA038069687A patent/CN1642567A/zh active Pending
- 2003-02-07 CA CA002475539A patent/CA2475539A1/en not_active Abandoned
- 2003-02-07 NZ NZ534492A patent/NZ534492A/en not_active IP Right Cessation
- 2003-02-07 NZ NZ579419A patent/NZ579419A/en not_active IP Right Cessation
- 2003-02-07 CN CNA038075164A patent/CN101166762A/zh active Pending
- 2003-02-07 KR KR1020107028953A patent/KR20110014661A/ko not_active Ceased
- 2003-02-07 EP EP09004575A patent/EP2090589A1/en not_active Withdrawn
- 2003-02-07 US US10/503,836 patent/US20060122374A1/en not_active Abandoned
- 2003-02-07 EP EP03737417A patent/EP1471928A1/en not_active Ceased
- 2003-02-07 WO PCT/IB2003/000433 patent/WO2003066085A1/en not_active Ceased
- 2003-02-07 AU AU2003244515A patent/AU2003244515A1/en not_active Abandoned
- 2003-02-07 EP EP03737416A patent/EP1471933A1/en not_active Withdrawn
- 2003-02-07 WO PCT/US2003/003616 patent/WO2003066824A2/en not_active Ceased
-
2004
- 2004-07-21 ZA ZA200405813A patent/ZA200405813B/en unknown
- 2004-07-21 ZA ZA200405811A patent/ZA200405811B/en unknown
-
2008
- 2008-12-23 AU AU2008264153A patent/AU2008264153A1/en not_active Abandoned
-
2009
- 2009-01-23 US US12/358,815 patent/US20090175893A1/en not_active Abandoned
- 2009-08-27 AU AU2009212820A patent/AU2009212820B2/en not_active Expired - Fee Related
- 2009-10-16 JP JP2009239593A patent/JP2010046076A/ja active Pending
-
2011
- 2011-10-31 US US13/285,727 patent/US20120263747A1/en not_active Abandoned
-
2013
- 2013-07-18 US US13/945,314 patent/US20140017273A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10774124B2 (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| JP2005538932A5 (OSRAM) | ||
| ES2661310T3 (es) | Proteínas mirac | |
| JP4324325B2 (ja) | 突然変異化ｉｌ１３−をベースとするキメラ分子 | |
| JPS6156197A (ja) | リンホトキシンの細胞溶解活性を中和する抗体 | |
| JPH11240897A (ja) | ウロキナーゼレセプター活性のペプチドインヒビター | |
| JP2001518304A (ja) | アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用 | |
| JP5208135B2 (ja) | 組換え白血球阻害因子とヒルゲンのキメラタンパク質及びその薬物組成物 | |
| JP5648637B2 (ja) | 血液脳関門障害改善剤 | |
| WO2002076486A2 (en) | Histidine-rich glycoprotein | |
| CN115028738A (zh) | 一种Fc融合蛋白双重靶向降解剂及应用 | |
| JPH10262668A (ja) | 血管形成誘導因子をコードするタンパク質コード配列を包含するｄｎａ配列 | |
| WO2005095443A1 (ja) | ペプチド改変を利用したドラッグデリバリーシステム | |
| JP2005534330A5 (OSRAM) | ||
| AU2013234365B2 (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| JP2022501373A (ja) | 改善された第ｖｉｉｉ因子長期半減期凝固複合体に関連する方法および組成物 | |
| AU2016216675A1 (en) | Protease resistant mmutants of stromal cell derived factor-1 in the repair of tissue damage | |
| HK1192845A (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| HK1192845B (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| HK1136211B (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| AU2002304352A1 (en) | Histidine-rich glycoprotein |